Rosetta Genomics (NASDAQ:ROSG) today announced the company’s upcoming
speaking events at the industry’s leading conferences.
Key representatives from Rosetta Genomics will be presenting data on the
company’s current and future microRNA-based tests. The events include:
|
-
|
|
Bio International Convention, Georgia Dome, Atlanta, Georgia -
Panel presentation titled “RNA Rx; the Next Wave of Therapeutics
beyond RNAi.” The presentation will take place on Wednesday, May
20, 4:00-5:30 pm, in Room B304.
|
|
|
|
-
|
|
American Society of Clinical Oncology (ASCO) 2009 Annual Meeting,
Orange County Convention Center, Orlando, Florida. Presentations
titled:
|
|
|
|
1. “A Validated New MicroRNA-Based Diagnostic Test for
Identification of Tumor Tissue Origin.” Session name: Tumor
Biology and Human Genetics. Monday, June 1, 1:00-5:00 pm. Level 2,
West Hall C.
|
|
|
|
|
|
|
|
2. “MicroRNA-Based Assay for Differential Diagnosis of Squamous
from Non-Squamous Non Small Cell Lung Carcinoma” Poster Session
and Discussion. Session name: Tumor Biology and Human Genetics.
Sunday, May 31, 2:00 PM to 6:00 PM Level 2, W240A. Discussion:
Sunday, May 31, 5:00 PM to 6:00 PM. Level 3, W304A.
|
|
|
|
-
|
|
Biomed 2009, David Intercontinental, Tel Aviv, Israel - Panel
discussion titled: “RNAi Therapeutics and Diagnostics.” The
presentation will take place on Monday, June 15, 12:10-1:30 pm.
|
|
|
|
-
|
|
13th World Conference on Lung Cancer, Moscone West, San Francisco,
California - July 31-August 4, 2009
|
Publications:
- Rosetta Genomics’ scientists, together with researchers from the Rabin
Medical Center in Israel, have published a study identifying an array of
tumor specific markers that are associated with response to platinum
based first line chemotherapy in ovarian cancer. The article “Tumor
microRNA expression patterns associated with resistance to platinum
based chemotherapy and survival in ovarian cancer patients,” published
in Gynecologic Oncology, is now available on-line at: http://www.sciencedirect.com/
“Rosetta Genomics is continuously advancing new assays and technologies
using microRNAs, including a blood-based test for the detection of colon
cancer,” said Amir Avniel, CEO and President of Rosetta Genomics. “In
light of the rapid advancements achieved over the past months, both
commercial and scientific, we feel it is critical that we share our
findings in the leading scientific conferences throughout the year.”
About Rosetta Genomics
Rosetta Genomics is a leading molecular diagnostics company developing
and commercializing molecular diagnostic products based on its
proprietary microRNAs. Rosetta Genomics is working to develop early
detection cancer screening products, including a colon cancer screening
test. Rosetta performs its commercial molecular diagnostics tests at
Rosetta Genomics Laboratories in Philadelphia.
Forward-Looking Statements
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects, including without limitation,
statements relating to the development of early detection cancer
screening products, including a non-invasive colon cancer screening
test, constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors,
including those risks more fully discussed under “Key Information - Risk
Factors” in Rosetta’s Annual Report on Form 20-F for the year ended
December 31, 2007 on file with the Securities and Exchange Commission.
In addition, any forward-looking statements represent Rosetta’s views
only as of today and should not be relied upon as representing its views
as of any subsequent date. Rosetta does not assume any obligation to
update any forward-looking statements unless required by law.
Company Contact:
Rosetta Genomics
Ron Kamienchick, 646-509-1893
investors@rosettagenomics.com
or
Investor
Contacts:
Lippert/Heilshorn & Associates
Kim Sutton
Golodetz, 212-738-3777
kgolodetz@lhai.com
or
Bruce
Voss, 310-691-7100
bvoss@lhai.com
